Biontech Se's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Biontech Se's ROA in the fourth quarter of 2025?
Biontech Se had a negative return on assets (ROA) of -5.71%, due to the net loss of $-1 billion, during the twelve months ending in the fourth quarter of 2025.

However, within the Healthcare sector 302 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 3470.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	4.75 %	-8.46 %	-8.46 %	-8.46 %	-2.51 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-1,272	-745	-745	-745	-745
Return On Assets (TTM)	-5.71 %	-3.38 %	-3.31 %	-3.24 %	-3.17 %
BNTX's Total Ranking	# 3470	#	#	#	# 3391
Total Assets (TTM) in million	24,627	21,521	21,521	21,521	23,510
Seq. Total Assets Change	14.44 %	0 %	0 %	-8.46 %	0 %
Seq. Net Income Change	-	-	-	-	-

BNTX's 5 Years Annual ROA >> Back to BNTX Management Effectiveness >> Compare BNTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 34
Sector	# 303
Overall	# 3443

Return On Assets Statistics
High	Average	Low
65.02 %	17.02 %	-5.17 %
(Dec 31 2021)		(Dec 31 2025)

Financial Statements
Biontech Se's Assets	$ 24,627 million	BNTX's Balance sheet
Biontech Se's Income	$ -1,272 million	Quarterly BNTX's Income Statement
BNTX's Income by Division		See BNTX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-8.46 %	-2.51 %	-6.3 %	47.34 %	603.02 %
Total Assets in million	21,521	23,510	24,116	25,738	17,469
Y / Y Net Income Change	-	-	-90.14 %	-8.34 %	67622.73 %
Net Income in million	-1,272	-745	1,042	10,567	11,528
Annual Return On Assets	-5.91 %	-3.17 %	4.32 %	41.05 %	65.99 %

BNTX's 5 Years Annual ROA >> Back to BNTX Management Effectiveness >> Compare BNTX ROA to its Competitors

More Return On Assets Ratios
BNTX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BNTX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BNTX's Competitors
Subscribers only: Roa for Biontech Se's Suppliers
Subscribers only: Return On Assets for BNTX's Customers

You may also want to know
BNTX's Roi	BNTX's Inventory Turnover Ratio	BNTX's Growth Rates	BNTX's Dividend Comparisons
	BNTX's Profitability Ratios	BNTX's Asset Turnover Ratio	BNTX's Dividend Growth
BNTX's Roe	BNTX's Valuation Ratios	BNTX's Financial Strength Ratios	BNTX's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-07-07T09:38:01+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.